Metastatic Colorectal Cancers Completed Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01640444Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)Treatment
NCT01163396First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal CancerTreatment
NCT02119026Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal CancerTreatment
NCT00819780PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) TumorsTreatment
NCT01321957Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal CancerTreatment
NCT00418938SPIRITT - Second-Line Panitumumab Irinotecan Treatment TrialTreatment
NCT02271464Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal CancerTreatment
NCT00875771Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer PatientsTreatment
NCT003456961stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.Treatment
NCT00378066Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon CancerTreatment
NCT00636610A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal CancerTreatment
NCT00862342Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)Treatment
NCT00959647A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer StudyTreatment
NCT01022541Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal CancerTreatment
NCT01024504Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal CancerTreatment
NCT01399684A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal CancerTreatment
NCT02821559Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal CancerTreatment